Clinical trial
A Phase I/II Study to Evaluate the Safety and Efficacy of Bicalutamide in Combination With Sunitinib in Patients With Receptor Tyrosine Kinase Inhibitor Resistant Renal Cell Carcinoma
NCT06222593 is registered in ClinicalTrials.gov with State University of New York at Buffalo as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I/II Study to Evaluate the Safety and Efficacy of Bicalutamide in Combination With Sunitinib in Patients With Receptor Tyrosine Kinase Inhibitor Resistant Renal Cell Carcinoma
- Lead sponsor
- State University of New York at Buffalo
- Phase
- Phase 1/2
- Overall status
- Recruiting
- Start date
- October 1, 2024
- Completion date
- July 1, 2027
- Enrollment
- 28 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.